Genomic testing is increasingly impacting prostate cancer diagnosis and treatment, helping clinicians make more informed management decisions based on the specific molecular characteristics of an individual patient’s cancer. In a video interview, Eric A. Klein, MD, Chairman of Cleveland Clinic’s Glickman Urological & Kidney Institute, discusses the broadening use of molecular-based tests.
Glickman Urological & Kidney Institute Chairman Eric Klein, MD, discusses advanced prostate cancer screening tests and prognostic tools developed at Cleveland Clinic and elsewhere that should help reduce unnecessary biopsies and allow clinicians to focus on high-risk patients.
Prostate cancer patients with an inherited gene mutation that enables intratumoral androgen synthesis are highly likely to develop resistance to androgen deprivation therapy and to die years earlier of their disease, researchers from Cleveland Clinic and Mayo Clinic have found. A screening test based on the mutation could inform clinical care.
Rather than abandoning routine prostate-specific antigen-based prostate cancer screening – a move that may have contributed to a recent rise in metastatic cancers – the right approach is to strategically use PSA and other diagnostic tools, says Glickman Urological & Kidney Institute Chairman Eric Klein, MD.
Cleveland Clinic Glickman Urological & Kidney Institute Chairman Eric Klein, MD, describes efforts to expand genomic testing to stratify good and bad outcomes in men with intermediate- and high-risk early-stage prostate cancer, and discusses advantages and challenges of the tests.
A new study reports that metastatic prostate cancer cases have sharply risen since 2007, possibly in part due to recommendations against routine screening. Eric Klein, MD, Chairman of Cleveland Clinic’s Glickman Urological & Kidney Institute, discusses how urologists have responded to concerns about false-positive screening test results and overtreatment.
Cleveland Clinic researchers have discovered a novel biochemical pathway that enables prostate cancer cells to survive extensive DNA damage that normally would trigger cell death. Blocking this modulatory pathway could increase cancer cells’ vulnerability to genotoxic therapies while sparing normal cells.
Androgen deprivation therapy, which prevents androgen receptor signaling, initially is effective against advanced prostate cancer but progression eventually resumes, relying on androgen receptor’s transcriptional activity. Cleveland Clinic researchers are exploring new approaches that block this transactivation function, which may prevent or overcome resistance.
A Cleveland Clinic study shows that gene expression patterns predictive of long-term prostate cancer outcomes, such as clinical recurrence after radical prostatectomy, are observable in normal tissue adjacent to tumor and may help identify patients with aggressive disease.
Pairing abiraterone with the enzyme inhibitor dutasteride modifies abiraterone’s metabolic conversion, blocking production of a prostate tumor-promoting metabolite while aiding accumulation of another metabolite that has strong anti-tumor effects, Cleveland Clinic researchers report.